News

Otivio featured in Norwegian financial newspaper Dagens Næringsliv

January 21, 2018

Otivio commences UK clinical trial

May 09, 2017

Oslo, Norway– (BUSINESS WIRE)– May 8th, 2017 — Otivio AS, a provider of FlowOx™, an innovative technology for improving blood flow in patients with reduced peripheral circulation, today announced the start of a pilot study to test the clinical efficacy of FlowOx™ home treatment compared to standard care in patients with critical limb ischemia and lower limb ulcers. The study is part of the Horizon 2020 Fast Track to Innovation grant from the EU awarded in 2016. The sponsor of the trial is the University of Salford, Manchester. The multi-centre pilot study will include 15 patients and initial recruitment will take place at Royal Oldham Hospital and later at additional centres. 

 “We are very pleased to cooperate with the University of Salford and Royal Oldham Hospital, leading centres on peripheral arterial disease in the UK”, says Iacob Mathiesen, founder and CSO of Otivio.

This project has received funding from the European Union's Horizon 2020 research and innovation programme, Fast Track To Innovation under grant agreement No: project 737964.

Iacob Mathiesen featured in Titan "Målet var ikke å bli gründer, men å få til ting"

May 02, 2017

FlowOx™ featured in diabetes.no

October 13, 2016

(Norwegian text)

Otivio Day launch

August 30, 2016

To celebrate our successes over the past 12 months and to share this with our stakeholders, Otivio Day was arranged on August 31st. Attendees included clinicians, FlowOx users (patients), shareholders, board members, employees and colleagues from the med tech industry.
During the presentation session, the audience learned about the disease, peripheral arterial disease (PAD), and the current treatment options through an insightful presentation given by Prof Raj Mani. In addition, our valuable clinical expert, Jonny Hisdal, PhD, talked about his clinical experience from the use of FlowOx.

Furthermore, Hans Thomas Meinich, our first FlowOx user, told his personal and touching story from his transition of being immobilized by the consequences of PAD, into his current pain free active life. All thanks to the use of what he refers to as the wonder machine – FlowOx. 

Before the most important agenda item – the food, drinks and mingling – Iacob and Andreas summarized the milestones reached this year and alluded to the exciting plans for the next two years.  
We will definitely repeat Otivio Day next year. Thank you all for participating and contributing to making this a great day.
 

Otivio awarded EU Horizon 2020 Fast Track to Innovation grant

August 15, 2016

Otivio AS, the company behind  FlowOx™, an innovative technology for improving blood flow in patients with reduced peripheral circulation, today announced it has been awarded a Horizon 2020 Fast Track to Innovation grant from the EU.


Otivio is the coordinator for the project which has partners in Finland and the UK. The grant is EUR 2.1 million and will fund the project over 30 months. Otivio is the first Norwegian company to be awarded this grant as a main applicant and coordinator. The project comprises of clinical documentation, product industrialization and commercialization of FlowOx™. University of Salford, Manchester, will be responsible for carrying out the clinical trials. The University of Bangor, Wales, will do the health economic analysis. Innokas Medical of Finland will be the main partner for product optimization and industrialization. There were close to 300 applicants for the grant. Out of these, 15 projects were awarded the grant. Otivio has received valuable assistance from Waqar Ahmed of Oslo Medtech and from the Norwegian Research Council in the application process.


“We are very proud to be selected for the grant. This proves the potential of FlowOx is significant and gives us funding to reach the markets with substantial clinical documentation and with a device which is optimized for high-volume production”, say Iacob Mathiesen, founder of Otivio and project leader for the application.  

Otivio hires new COO

May 12, 2016

Oslo, Norway (BUSINESS WIRE)  Otivio AS, the company behind FlowOx™ , an innovative technology for improving blood flow in patients with reduced peripheral circulation, today announced it has employed Arnar Kristjánsson as their new COO.

Arnar, Icelandic by nationality, has experience from several industries including med tech. He holds a diploma engineer degree from the Technical University of Berlin and a Master’s Degree from Chalmers University of Technology in Sweden. In addition, he has a PhD degree in Engineering Design from the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway.

Arnar comes from the position of Business Development Engineer in GE Oil and Gas, Norway. Prior to this, he was Global Product Manager with Össur, an Icelandic multinational company with a wide range of medical technology products. In addition to this, he has experience from banking as well as consultancy work.

Arnar has an impressive background and brings skills that are complimentary to the Otivio team, says Andreas Mollatt, CEO of Otivio. He will be an important member of the management team. Arnar will start in his position on August 15th, 2016.

Article in Norwegian financial newspaper Dagens Næringsliv

May 11, 2016

FlowOx™ to be presented at the Charing Cross International Symposium

April 20, 2016

Oslo, Norway (BUSINESS WIRE) Otivio AS, the company behind FlowOx™, an innovative technology for improving blood flow in patients with reduced peripheral circulation, today announced that clinical data from the use of FlowOx™ will be presented at the Charing Cross International Symposium in London, UK, on April 26th and April 28th 2016.

Participants include world leading clinicians and researchers within the vascular and endovascular area and FlowOx™ will be the only Norwegian technology to be presented during the symposium. The presentations will be given by Jonny Hisdal, PhD, physiologist at Oslo University Hospital, Norway.. Dr. Hisdal has vast experience from the use of FlowOx™.

“We are very excited that Jonny Hisdal has been invited to present during Charing Cross International Symposium says Andreas Mollatt, CEO of Otivio. Our long-standing cooperation with Oslo University Hospital has been excellent and is a good example on how innovative clinical centers can be paramount for developing new technologies for the benefit of patients and the society.”

The FlowOx™ is a novel system for treatment of peripheral arterial disease (PAD). PAD, also called peripheral vascular disease, is a narrowing of the blood vessels (arteries). It mainly occurs in arteries that supply blood to the legs. This is a disease leading to leg pain and chronic wounds due to decreased blood flow to the legs. The system will be evaluated further in post market studies in order to better document its ability to help patients with diabetes related circulatory problems, patients with intermittent claudication or, critical limb ischemia.

Otivio to present FlowOx™ on Demo Day in United States Congress

February 04, 2016

Oslo, Norway (BUSINESS WIRE) Otivio AS, the company behind FlowOx™, an innovative technology for improving blood flow in patients with reduced peripheral circulation, today announced that the company will present its FlowOx™ system at Demo Day in the United States Congress.

Otivio will be one of four companies to present on Demo Day on February 9, 2016. The other companies are Hucon Global Ltd, Skannex AS and Smartfish AS. The event has been coordinated by Oslo Medtech, Innovation Norway, American Defence International and U.S. Representative Rick Larsen, Co-Chair of the Friends of Norway Caucas in the US Congress. The delegates present on Demo Day include high ranked politicians, health care officers, military officers, health care industry delegates and press.

“We are excited to be selected to present on Demo Day” said Iacob Mathiesen, CEO, Otivio. “The event gives us a unique opportunity connect with influential partners”.  Otivio expects that FlowOx™ will be introduced in the US market in 12-18 months.

FlowOx™ is a novel system for treatment of peripheral arterial disease (PAD). Otivio has developed FlowOx™ for patients with cold feet, leg pain and chronic wounds which can be symptoms of PAD. Early long-term testing documents increased blood flow, pain reduction and wound healing.

Otivio announces approval for CE Mark of FlowOx™

August 05, 2014

Oslo, Norway (BUSINESS WIRE) Otivio AS, a leading provider of innovative technologies for improving blood flow in patients with reduced peripheral circulation, today announced its FlowOx™ blood flow enhancer has received European Economic Area (EEA) CE Mark approval.

The new home care device from Otivio — designed to be simple, safe and smart — enables patients to transiently improve blood flow to their limbs using the most innovative negative pressure technology available.

“We are excited to introduce our first commercial version of the FlowOx system,” said Iacob Mathiesen, CEO, Otivio. “Building on Otivio’s strong legacy of innovation, the FlowOx™ device will provide clinicians with a simple, safe and smart way to enhance blood flow to the legs of a patient.”

The FlowOx™ system is for patients with various problems associated with reduced peripheral circulation. The patient group that may benefit from this system suffer from a condition called Peripheral Arterial Occlusive Disease. The system will be evaluated further in post market studies in order to better document its ability to help patients with diabetes related circulatory problems, patients with intermittent claudication, and with critical limb ischemia.

Otivio completes and passes ISO 13485 certification audit

April 09, 2014

Oslo, Norway (Business Wire)  Otivio AS, a medical device company focused on developing and commercializing medical devices for prevention and treatment of peripheral arterial occlusive disease. The company which is also developing  a patient temperature management system, announced today receipt of ISO 13485:2012 certification.  The ISO 13485 certificate is awarded by NEMKO (Norway) and is the globally recognized standard that defines quality system requirements for the design and manufacturing of medical devices, including many supply chain functions such as assembly, packaging, warehousing and distribution.  Compliance with ISO 13485 is a step towards achieving compliance with European regulatory requirements for marketing medical devices.  Otivio anticipates a final review and determination regarding its CE Mark application within the next few weeks.

“This certification represents a major achievement and milestone for Otivio. The successful completion assists us in moving forward with regulatory registrations,” said Enda Kenny, PhD, the Company’s Chief Operating Officer.

The ISO 13485:2012 certification is a stand-alone standard developed by the International Organization for Standardization that provides harmonized quality management systems requirements for manufacturers of medical devices.   It is adopted by the European Commission as proof of conformity with EU regulations for design, development and manufacturing of medical devices according to EECdecrees 93/42/EEC, 90/385/EEC and 98/79/EEC.  In accordance with EU regulations, conformance is confirmed by a Notified Body before sale of a medical device is permitted.

Please reload

© 2023 by Gracious Dwelling. Proudly created with Wix.com

  • Facebook - Grey Circle

|  +47 934 46 261   |   info@otivio.com